2
|
Gochman A, Do TQ, Kim K, Schwarz JA, Thorpe MP, Blackwell DJ, Ritschel PA, Smith AN, Rebbeck RT, Akers WS, Cornea RL, Laver DR, Johnston JN, Knollmann BC. ent-Verticilide B1 Inhibits Type 2 Ryanodine Receptor Channels and is Antiarrhythmic in Casq2 -/- Mice. Mol Pharmacol 2024; 105:194-201. [PMID: 38253398 PMCID: PMC10877729 DOI: 10.1124/molpharm.123.000752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 12/20/2023] [Accepted: 01/02/2024] [Indexed: 01/24/2024] Open
Abstract
Intracellular Ca2+ leak from cardiac ryanodine receptor (RyR2) is an established mechanism of sudden cardiac death (SCD), whereby dysregulated Ca2+ handling causes ventricular arrhythmias. We previously discovered the RyR2-selective inhibitor ent-(+)-verticilide (ent-1), a 24-membered cyclooligomeric depsipeptide that is the enantiomeric form of a natural product (nat-(-)-verticilide). Here, we examined its 18-membered ring-size oligomer (ent-verticilide B1; "ent-B1") in RyR2 single channel and [3H]ryanodine binding assays, and in Casq2 -/- cardiomyocytes and mice, a gene-targeted model of SCD. ent-B1 inhibited RyR2 single channels and RyR2-mediated spontaneous Ca2+ release in Casq2 -/- cardiomyocytes with sub-micromolar potency. ent-B1 was a partial RyR2 inhibitor, with maximal inhibitory efficacy of less than 50%. ent-B1 was stable in plasma, with a peak plasma concentration of 1460 ng/ml at 10 minutes and half-life of 45 minutes after intraperitoneal administration of 3 mg/kg in mice. In vivo, ent-B1 significantly reduced catecholamine-induced ventricular arrhythmias in Casq2 -/- mice in a dose-dependent manner. Hence, we have identified a novel chemical entity - ent-B1 - that preserves the mechanism of action of a hit compound and shows therapeutic efficacy. These findings strengthen RyR2 as an antiarrhythmic drug target and highlight the potential of investigating the mirror-image isomers of natural products to discover new therapeutics. SIGNIFICANCE STATEMENT: The cardiac ryanodine receptor (RyR2) is an untapped target in the stagnant field of antiarrhythmic drug development. We have confirmed RyR2 as an antiarrhythmic target in a mouse model of sudden cardiac death and shown the therapeutic efficacy of a second enantiomeric natural product.
Collapse
Affiliation(s)
- Aaron Gochman
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Tri Q Do
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Kyungsoo Kim
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Jacob A Schwarz
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Madelaine P Thorpe
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Daniel J Blackwell
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Paxton A Ritschel
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Abigail N Smith
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Robyn T Rebbeck
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Wendell S Akers
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Razvan L Cornea
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Derek R Laver
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Jeffrey N Johnston
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| | - Bjorn C Knollmann
- Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (A.G., T.Q.D. K.K., D.J.B., P.A.R., B.C.K.); Vanderbilt Department of Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (M.P.T., A.N.S., J.N.J.); Pharmaceutical Sciences Research Center, Lipscomb University College of Pharmacy, Nashville, Tennessee (W.S.A.); Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota (J.A.S., R.L.C., R.T.R.); and School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia (D.R.L.)
| |
Collapse
|